Myriad Genetics agrees to sell prenatal testing business to Labcorp for $210 million plus inventory value

• Myriad Genetics agreed to sell its prenatal testing business to Labcorp for $210 million cash, with inventory value payable at closing.
• The transaction is expected to close by early 2027.
• Labcorp expects approximately $160 million in first-year revenue from the business, with slight accretion to adjusted earnings.
• The acquired business is expected to reach average diagnostics segment margins by the end of year two, once fully integrated.
• The sale is expected to strengthen the seller’s balance sheet, supporting investment in its cancer care priorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200830PRIMZONEFULLFEED9849207) on October 20, 2026, and is solely responsible for the information contained therein.